International Clinical Trial: A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Dapagliflozin tablets 10 mg, relative to Forxiga tablets 10 mg in healthy Thai participants under fasting condition

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260416005) titled 'A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Dapagliflozin tablets 10 mg, relative to Forxiga tablets 10 mg in healthy Thai participants under fasting condition' on April 16.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: Bio-innova Co., Ltd.

Condition: Healthy volunteers Bioequivalence Dapagliflozin tablets 10 mg Bioequivalence Dapagliflozin tablets 10 mg

Intervention: The new generic products which were recently developed. Volunteer will receive a single dose of Dapagliflozin tablets 10...